Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Saxenda often causes diarrhea due to its effects on slowing gastric emptying, altering gut motility, and increasing fluid secretion, with up to 20-30% of users experiencing loose stools, especially during dose escalation. Most cases are mild and manageable with dietary tweaks, hydration, proper medication timing, and symptom monitoring, but persistent or severe episodes can lead to dehydration and nutrient loss.
Deciding whether to switch medications depends on factors such as symptom severity, quality-of-life impact, and alternative options like other GLP-1 agonists or non-GLP-1 weight-loss drugs, so see the complete considerations below.
Saxenda (liraglutide) is a popular prescription medication for weight management. While many people see benefits in appetite control and weight loss, gastrointestinal side effects—especially diarrhea—are frequently reported. Understanding why Saxenda causes diarrhea, how common it is, and when to consider switching medications can help you stay on track with your treatment plan.
Saxenda is part of the GLP-1 receptor agonist class of drugs, originally developed to improve blood sugar control in type 2 diabetes. Its weight‐loss benefit comes from:
These same actions can lead to diarrhea in several ways:
Altered intestinal motility
– SLowed gastric emptying means food reaches the small intestine in a less broken‐down form.
– The intestine may compensate by speeding transit downstream, leading to looser stools.
Changes in fluid and electrolyte balance
– GLP-1 agonists can increase secretion of chloride and water into the gut lumen.
– This extra fluid can overwhelm normal absorption, resulting in diarrhea.
Modifications of gut hormone levels
– Saxenda impacts hormones like motilin, gastrin, and peptide YY, which regulate digestion.
– Imbalances may disrupt normal stool consistency.
Potential alterations in gut microbiota
– Some studies suggest GLP-1 therapy may change gut bacteria balance.
– Dysbiosis (microbial imbalance) can contribute to diarrhea.
Clinical trials and patient reports show gastrointestinal side effects are among the most frequent issues:
Most Saxenda-related diarrhea is short‐lived and manageable. However, persistent or severe diarrhea can lead to:
Seek medical attention if you experience:
If you're uncertain about the seriousness of your symptoms, you can get personalized guidance using a Medically approved LLM Symptom Checker Chat Bot to help determine whether you need immediate medical attention or can manage symptoms at home.
For many, simple lifestyle and dietary tweaks can ease symptoms:
Deciding whether to continue Saxenda or switch to another weight‐loss treatment depends on several factors:
Each alternative has its own side effects and effectiveness profile. A collaborative discussion with your healthcare provider is key.
Diarrhea on Saxenda can be uncomfortable, but it's often manageable with simple lifestyle changes and patience during the dose‐adjustment period. If symptoms are severe or persistent, don't hesitate to seek medical advice or check your symptoms using a Medically approved LLM Symptom Checker Chat Bot for immediate guidance. Always remember:
Speak to a doctor about any symptoms that are life‐threatening, persistent, or concerning. Your healthcare provider can help you weigh the benefits of Saxenda against any side effects and find the best path forward for your health and weight‐loss goals.
(References)
* Yang, K., Peng, S., Yang, M., Jiang, S., Zhang, D., & Yang, B. (2020). Gastrointestinal Tolerability of Liraglutide for Weight Management: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Obesity Reviews*, *21*(4), e12999.
* Nauck, M. A. (2021). Mechanisms underlying the gastrointestinal side effects of GLP-1 receptor agonists. *Lancet Diabetes & Endocrinology*, *9*(9), 569-583.
* Wilding, J. P. H., Batterham, R. L., Davies, M. J., Forhan, S. E., Van Gaal, L. F., & Jensen, C. B. (2018). The effect of liraglutide 3.0 mg on gastrointestinal adverse events in the SCALE Obesity and Prediabetes trial. *Journal of Medical Economics*, *21*(9), 920-928.
* Smits, M. M., & Van Raalte, D. H. (2021). Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Focus on Clinical Implications. *Drug Safety*, *44*(11), 1159-1175.
* O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., ... & Wilding, J. P. H. (2019). Efficacy and safety of liraglutide 3.0 mg in obese and overweight adults: a review of efficacy and safety. *Diabetes, Obesity and Metabolism*, *21*(5), 1083-1092.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.